| Literature DB >> 22306856 |
Akiko Kikukawa1, Yasuyuki Gomi, Masateru Akechi, Toshiyuki Onishi, Sadao Manabe, Junko Namazue, Isao Fuke, Toyokazu Ishikawa, Yoshinobu Okuno, Shigeharu Ueda.
Abstract
Japanese encephalitis is an infectious disease caused by the Japanese encephalitis virus, which is widespread throughout Asia. The worldwide incidence is 50,000 cases per year. There is no specific treatment available, but inactivated mouse brain-derived vaccine was used from the 1950s to prevent infection. However, quality control of mouse brain-derived vaccines is difficult, and therefore a new freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated) (JEBIK V; development code: BK-VJE) was developed. In this paper, we report an analysis of neutralizing antibody titers in vaccinated subjects enrolled in clinical study of BK-VJE at various doses, and study of BK-VJE with the mouse brain-derived vaccine as a control. The results show that BK-VJE has superior immunogenicity compared to mouse brain-derived vaccine. Copyright ÂEntities:
Mesh：
Substances：
Year: 2012 PMID： 22306856 DOI： 10.1016/j.vaccine.2012.01.054
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641